Skip to main content

NASDAQ:NTLA - Intellia Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $67.54
  • Forecasted Upside: -0.30 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$67.74
▲ +1.26 (1.90%)
1 month | 3 months | 12 months
Get New Intellia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTLA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$67.54
▼ -0.30% Downside Potential
This price target is based on 15 analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $67.54, with a high forecast of $110.00 and a low forecast of $20.00. The average price target represents a -0.30% upside from the last price of $67.74.

Buy

The current consensus among 15 polled investment analysts is to buy stock in Intellia Therapeutics. This rating has held steady since June 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021Roth CapitalUpgradeNeutral ➝ Buy$75.00 ➝ $80.00Medium
i
Rating by T. Butler at Roth Capital
5/3/2021Royal Bank of CanadaInitiated CoverageOutperform$110.00Medium
i
3/21/2021SVB LeerinkReiterated RatingBuyHigh
i
Rating by M. Foroohar at SVB Leerink LLC
3/10/2021JMP SecuritiesInitiated CoverageOutperform$80.00N/A
i
3/4/2021JMP SecuritiesInitiated CoverageOutperform$80.00High
i
2/26/2021TruistBoost Price Target$40.00 ➝ $80.00High
i
2/10/2021Chardan CapitalBoost Price TargetBuy$57.50 ➝ $85.00Low
i
1/8/2021Raymond JamesBoost Price TargetOutperform$39.00 ➝ $106.00High
i
1/8/2021BarclaysBoost Price TargetOverweight$46.00 ➝ $90.00Low
i
12/22/2020Robert W. BairdDowngradeOutperform ➝ Neutral$60.00High
i
12/21/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $61.00High
i
Rating by M. Foroohar at SVB Leerink LLC
12/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$38.00 ➝ $52.00Medium
i
11/5/2020SVB LeerinkReiterated RatingOutperformMedium
i
Rating by M. Foroohar at SVB Leerink LLC
10/27/2020TruistInitiated CoverageBuy$40.00 ➝ $40.00High
i
10/27/2020Summer StreetInitiated CoverageBuyHigh
i
10/19/2020Roth CapitalBoost Price TargetReduce ➝ Neutral$16.00 ➝ $26.00Low
i
10/14/2020Wells Fargo & CompanyInitiated CoverageOverweightMedium
i
9/30/2020OppenheimerReiterated RatingHoldHigh
i
9/18/2020The Goldman Sachs GroupInitiated CoverageBuy$33.00High
i
8/6/2020Chardan CapitalReiterated RatingBuyHigh
i
Rating by Geulah Livshits at Chardan Capital
6/2/2020Credit Suisse GroupBoost Price TargetNeutral$19.00 ➝ $21.00High
i
6/1/2020WedbushBoost Price TargetNeutral$16.00 ➝ $20.00High
i
Rating by D. Nierengarten at Wedbush
6/1/2020Chardan CapitalReiterated RatingBuy$57.50High
i
Rating by Geulah Livshits at Chardan Capital
5/8/2020OppenheimerReiterated RatingHoldLow
i
Rating by Silvan Tuerkcan at Oppenheimer Holdings Inc.
4/2/2020BTIG ResearchReiterated RatingBuy$22.00Low
i
Rating by Amanda Murphy at BTIG Research
3/31/2020Chardan CapitalReiterated RatingBuy$57.50High
i
Rating by Geulah Livshits at Chardan Capital
2/28/2020OppenheimerUpgradeMarket Perform ➝ OutperformHigh
i
2/14/2020WedbushDowngradeOutperform ➝ Neutral$21.00 ➝ $16.00High
i
Rating by D. Nierengarten at Wedbush
2/10/2020Chardan CapitalReiterated RatingBuy$57.50Low
i
Rating by Geulah Livshits at Chardan Capital
1/9/2020Chardan CapitalReiterated RatingBuy$57.50Medium
i
Rating by Geulah Livshits at Chardan Capital
11/1/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$24.00High
i
9/27/2019Chardan CapitalSet Price TargetBuy$57.50High
i
Rating by Geulah Livshits at Chardan Capital
7/8/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$23.00Medium
i
6/10/2019Roth CapitalInitiated CoverageNeutral$16.00High
i
Rating by T. Butler at Roth Capital
5/28/2019Chardan CapitalReiterated RatingBuy$57.50Low
i
5/3/2019WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $21.00High
i
Rating by D. Nierengarten at Wedbush
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
i
2/27/2019Chardan CapitalReiterated RatingBuy$57.50High
i
2/7/2019BTIG ResearchInitiated CoverageBuy$20.00High
i
11/27/2018SVB LeerinkInitiated CoverageOutperform$23.00High
i
Rating by M. Foroohar at SVB Leerink LLC
11/2/2018WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $20.00Medium
i
Rating by D. Nierengarten at Wedbush
10/31/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
10/29/2018Credit Suisse GroupInitiated CoverageNeutral ➝ Neutral$24.00High
i
Rating by Martin Auster at Credit Suisse Group AG
9/20/2018Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformHigh
i
8/24/2018Chardan CapitalReiterated RatingBuy$57.50Low
i
5/18/2018WedbushReiterated RatingOutperform$36.00High
i
5/15/2018Chardan CapitalUpgradeNeutral ➝ BuyHigh
i
3/15/2018WedbushReiterated RatingOutperform$36.00High
i
3/14/2018SVB LeerinkReiterated RatingOutperformHigh
i
Rating by J. Schwartz at SVB Leerink LLC
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ OutperformHigh
i
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$33.00 ➝ $46.00Medium
i
12/18/2017OppenheimerReiterated RatingHoldLow
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/12/2017OppenheimerReiterated RatingHoldHigh
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/5/2017BarclaysReiterated RatingBuyN/A
i
11/3/2017Credit Suisse GroupBoost Price TargetOutperform$24.00 ➝ $28.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
10/31/2017Jefferies Financial GroupSet Price TargetBuy ➝ Buy$36.00 ➝ $42.00N/A
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
10/31/2017SVB LeerinkBoost Price TargetOutperform$29.00 ➝ $37.00N/A
i
10/3/2017Jefferies Financial GroupReiterated RatingBuy$36.00High
i
9/27/2017WedbushReiterated RatingOurperform$29.00 ➝ $25.00High
i
9/6/2017BarclaysInitiated CoverageOverweight$29.00Low
i
8/29/2017Chardan CapitalDowngradeBuy ➝ Neutral$20.00High
i
Rating by Madhu Kumar at Chardan Capital
8/2/2017Chardan CapitalReiterated RatingBuy$19.00 ➝ $20.00Low
i
Rating by Madhu Kumar at Chardan Capital
7/22/2017Jefferies Financial GroupReiterated RatingBuy$36.00High
i
7/18/2017OppenheimerInitiated CoverageMarket PerformHigh
i
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$36.00Low
i
Rating by Gena Wang at Jefferies Financial Group Inc.
6/3/2017Credit Suisse GroupSet Price TargetBuy$24.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/15/2017WedbushReiterated RatingOutperform$25.00High
i
5/3/2017Credit Suisse GroupSet Price TargetBuy$24.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/3/2017WedbushReiterated RatingOutperform$25.00High
i
3/27/2017Chardan CapitalInitiated CoverageBuy ➝ Buy$19.00Medium
i
3/14/2017WedbushReiterated RatingOutperform$25.00Low
i
2/16/2017WedbushReiterated RatingOutperform$25.00N/A
i
2/8/2017Jefferies Financial GroupReiterated RatingBuy$33.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
1/11/2017Jefferies Financial GroupSet Price TargetBuy$33.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
1/5/2017SVB LeerinkReiterated RatingOutperformN/A
i
Rating by J. Schwartz at SVB Leerink LLC
12/12/2016Jefferies Financial GroupSet Price TargetBuy$33.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
11/3/2016Jefferies Financial GroupReiterated RatingBuy$33.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
10/21/2016WedbushReiterated RatingOutperform$38.00N/A
i
Rating by David Nierengarten at Wedbush
10/5/2016Jefferies Financial GroupSet Price TargetBuy$33.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
9/28/2016Janney Montgomery ScottInitiated CoverageBuy$29.00N/A
i
8/23/2016WedbushReiterated RatingOutperform$38.00N/A
i
Rating by David Nierengarten at Wedbush
8/17/2016Jefferies Financial GroupReiterated RatingBuy$33.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
8/5/2016SVB LeerinkUpgradeMarket Perform ➝ Outperform$32.00N/A
i
Rating by M. Schmidt at SVB Leerink LLC
8/5/2016Jefferies Financial GroupUpgradeHold ➝ Buy$33.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
5/31/2016SVB LeerinkInitiated CoverageMarket Perform$32.00N/A
i
Rating by M. Schmidt at SVB Leerink LLC
5/31/2016WedbushInitiated CoverageOutperform$38.00N/A
i
Rating by D. Nierengarten at Wedbush
5/31/2016Jefferies Financial GroupInitiated CoverageHold$33.00N/A
i
5/31/2016Credit Suisse GroupInitiated CoverageOutperform$39.00N/A
i
(Data available from 5/9/2016 forward)
Intellia Therapeutics logo
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $67.74
$67.33
$74.00

50 Day Range

MA: $72.65
$61.21
$87.07

52 Week Range

Now: $67.74
$13.22
$92.00

Volume

1,075,261 shs

Average Volume

1,555,534 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Intellia Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Intellia Therapeutics in the last year: Barclays PLC, Chardan Capital, Credit Suisse Group AG, JMP Securities, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Roth Capital, Royal Bank of Canada, Summer Street, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NTLA.

What is the current price target for Intellia Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Intellia Therapeutics in the last year. Their average twelve-month price target is $67.54, suggesting a possible downside of 0.3%. Royal Bank of Canada has the highest price target set, predicting NTLA will reach $110.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $20.00 for Intellia Therapeutics in the next year.
View the latest price targets for NTLA.

What is the current consensus analyst rating for Intellia Therapeutics?

Intellia Therapeutics currently has 4 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTLA will outperform the market and that investors should add to their positions of Intellia Therapeutics.
View the latest ratings for NTLA.

What other companies compete with Intellia Therapeutics?

How do I contact Intellia Therapeutics' investor relations team?

Intellia Therapeutics' physical mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company's listed phone number is 857-285-6200 and its investor relations email address is [email protected] The official website for Intellia Therapeutics is www.intelliatx.com.